Natera Launches Zenith Genomic Assay for Rare Disease Diagnosis

Natera has launched Zenith, a genomic assay designed to improve rare disease diagnosis. The assay aims to shorten the diagnostic odyssey for the 30 million Americans affected by rare diseases, which have a cumulative economic burden of nearly $997 billion in 2019. Morgan Stanley lowered its price target on Natera from $265 to $250, while keeping an Overweight rating on the company's stock.